United States - English - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas cabergoline tablets, usp are contraindicated in patients with - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cabergoline - tablet - cabergoline 0.5 mg - other gynecologicals

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cabergoline, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: leucine; lactose - indications as at 10 june 2004 : inhibition of physiological lactation - dostinex is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. treatment of hyperprolactinemic disorders - dostinex is indicated for the treatment of pathological hyperprolactinaemia.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, diameter: 5.5 mm, thickness: 2.9 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, diameter: 5.5 mm, thickness: 2.9 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, major axis: 7.4 mm, minor axis: 3.8 mm, thickness: 2.9 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - cabergoline - white tablet, major axis: 7.4 mm, minor axis: 3.8 mm, thickness: 2.9 mm

Ireland - English - HPRA (Health Products Regulatory Authority)

arrow generics limited - cabergoline - tablets - 0.5 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - cabergoline, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: leucine; lactose monohydrate - inhibition of physiological lactation. prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. treatment of hyperprolactinaemic disorders. treatment of pathological hyperprolactinaemia.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - cabergoline - tablets - cabergoline 2 mg - cabergoline - cabergoline - parkinson's disease. combination therapy with l-dopa and as monotherapy for newly diagnosed illness.